Estimate based on the three major studies which provided data on clinical mastitis incidence rates (5407, 5422, 20). In the control cows in these studies, there were 441 cases in 975 lactations = 45 cases / 100 lactations.
Of the 441 cases reported above, 345 (78%) occurred during the treatment period.
In Section 7.1.2 of this report the estimate of the increased risk of clinical mastitis associated with rbST use was 25% - 30%. 25% represents a slightly conservative estimate.
This estimate is based on a standard lactation curve with peak production of 39Kg/day and a persistency value of 0.133
In section 4.1.2 the increase in FCM was estimated to be 11.4% in primiparous cows and 15.6% in multiparous cows. However, it was noted that these results were obtained in institutional herds under very intensive nutritional management. Consequently, a more conservative estimate of 10% has been selected.
This is just a hypothetical herd for the purpose of the following calculations.
45 cases distributed as:
10 cases before 60 days
35 x 1.25 = 43.75 cases after day 60
Total = 53.75 cases
If the producer keeps milking 100 cows, we can expect an extra 8.75 cases of mastitis per 100 lactations. This represents an overall increase of 19.4%
100 cows would produce:
100 x 8000 x 0.23 = 184,000 l before day 60
100 x 8000 x .77 x 1.1 = 677,600 l after day 60
Total production = 861,600 l (or an overall increase of 7.7%)
If the producer reduce the herd size by 7.7% to keep milk production constant, he would expect to have:
53.75 / 1.077 = 49.9 cases of clinical mastitis for a net increase of 4.9 cases of mastitis per 100 lactations. This represents an overall increase of 10.9%